Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study

被引：1

作者：

Rugo, H. S. ^{[1
]}

O'Shaughnessy, J. ^{[2
]}

Cortes, J. ^{[3
]}

Bardia, A. ^{[4
]}

Hamilton, E. P. ^{[5
]}

Hurvitz, S. A. ^{[6
]}

Kaklamani, V. ^{[7
]}

Mchayleh, W. ^{[8
]}

Romero, P. Munoz ^{[9
]}

Vallespir, B. Piza ^{[10
]}

Wasserman, T. ^{[11
]}

Theall, K. P. ^{[12
]}

Tolaney, S. M. ^{[13
]}

机构：

[1] UCSF Helen Diller Family Comprehens Canc Ctr, Breast Dept, San Francisco, CA USA

[2] Baylor Univ, Med Ctr, Texas Oncol, Med Oncol Dept,US Oncol, Dallas, TX USA

[3] Quironsalud Grp, Int Breast Canc Ctr IBCC, Med Oncol Dept, Barcelona, Spain

[4] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Univ Calif Los Angeles UCLA Hlth, Med Oncol Dept, Los Angeles, CA 90024 USA

[5] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA

[6] Univ Washington, Fred Hutchinson Canc Ctr, Med Hematol Oncol Dept, Seattle, CA USA

[7] Univ Texas Hlth Sci Ctr San Antonio, Med Oncol Dept, San Antonio, TX 78229 USA

[8] AdventHlth Canc Inst, Oncol, Orlando, FL USA

[9] Menarini Grp, Biostat & Data Management Dept, Florence, Italy

[10] Menarini Grp, Clin Sci Dept, Florence, Italy

[11] Menarini Grp, Global Med Affairs Dept, Florence, Italy

[12] Menarini Grp, Global Prod Dev Dept, New York, NY USA

[13] Dana Farber Canc Inst, Med Oncol Dept, Boston, MA 02115 USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.317

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

369P

引用

页码：S372 / S373

页数：2

共 50 条

[1] Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study
Rugo, Hope S.
O'Shaughnessy, Joyce
Cortes, Javier
Bardia, Aditya
Hamilton, Erika P.
Hurvitz, Sara A.
Kaklamani, Virginia G.
Romero, Paula Munoz
Vallespir, Bartomeu Piza
Wasserman, Tomer
Theall, Kathy Puyana
Tolaney, Sara M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
Rugo, Hope
Bardia, Aditya
Cortes, Javier
Curigliano, Giuseppe
Hamilton, Erika
Hurvitz, Sara
Loibl, Sibylle
Tolaney, Sara
Kaklamani, Virginia
Tonini, Giulia
Matheny, Shannon
Theall, Kathy Puvana
O'Shaughnessy, Joyce
CANCER RESEARCH, 2024, 84 (09)
[3] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
Rugo, Hope S.
Bardia, Aditya
Cortes, Javier
Curigliano, Giuseppe
Hamilton, Erika
Hurvitz, Sara A.
Loibl, Sibylle
Kummel, Sherko
Scartoni, Simona
Matheny, Shannon
Theall, Kathy Puyana
O'shaughnessy, Joyce
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 32 - 32
[4] Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
Ciruelos, E. M.
Hamilton, E. P.
Kim, S-B.
Im, Y-H.
Solis, E. Segui
Saenz, J. A. Garcia
Di Sanzo, A.
Lizarbe, M. Dominguez
Wasserman, T.
Theall, K. P.
Ibrahim, N. K.
ANNALS OF ONCOLOGY, 2024, 35 : S370 - S370
[5] Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study
Ibrahim, Nuhad K.
Hamilton, Erika P.
Kim, Sung-Bae
Im, Young-Hyuck
Segui, Elia
Garcia-Saenz, Jose A.
Di Sanzo, Alessandro
Vallespir, Bartomeu Piza
Lizarbe, Manuel Dominguez
Wasserman, Tomer
Theall, Kathy Puyana
Ciruelos, Eva
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
Hamilton, Erika
Kim, Sung-Bae
Awada, Ahmad
Lin, Nancy
Zuefle, Sebastian
Scartoni, Simona
Vallespir, Bartomeu Piza
Theall, Kathy Puyana
Ibrahim, Nuhad
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 30 - 31
[7] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
Hamilton, Erika
Kim, Sung-Bae
Lin, Nancy U.
Awada, Ahmad
Gil, Eva Ciruelos
Di Sanzo, Alessandro
Vallespir, Bartomeu Piza
Theall, Kathy Puyana
Ibrahim, Nuhad
CANCER RESEARCH, 2024, 84 (07)
[8] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
Ibrahim, Nuhad
Kim, Sung-Bae
Lin, Nancy
Awada, Ahmad
Gil, Eva Ciruelos
Tonini, Giulia
Vallespir, Bartomeu Piza
Theall, Kathy Puvana
Hamilton, Erika
CANCER RESEARCH, 2024, 84 (09)
[9] ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancer
Hamilton, Erika
Pusztai, Lajos
Soliman, Hatem H.
Hurvitz, Sara
Grzegorzewski, Krzysztof
Habboubi, Nassir
Marreddy, Priya
Sahmoud, Tarek
Ibrahim, Nuhad
CANCER RESEARCH, 2023, 83 (05)
[10] acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).
Martin, Miguel
Lim, Elgene
Mac Gregor, Mariana Chavez
Shivhare, Mahesh
Ross, Graham
Patre, Monika
Roncoroni, Laura
Louka, Maria
Sohn, Joohyuk
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →